| Macular retinal edema
Ozurdex vs Vabysmo
Side-by-side clinical, coverage, and cost comparison for macular retinal edema.Deep comparison between: Ozurdex vs Vabysmo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVabysmo has a higher rate of injection site reactions vs Ozurdex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vabysmo but not Ozurdex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ozurdex
Vabysmo
At A Glance
Intravitreal injection
Corticosteroid
Intravitreal injection
Every 4-8 weeks
VEGF-A and Ang-2 inhibitor
Indications
- Macular retinal edema
- Uveitis
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Macular retinal edema
Dosing
Macular retinal edema, Uveitis One 0.7 mg intravitreal implant injected into the vitreous cavity under controlled aseptic conditions; each applicator is single-use and treats one eye only.
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection every 4 weeks for first 4 doses, followed by dosing every 8, 12, or 16 weeks based on OCT and visual acuity evaluations; some patients may need every 4-week dosing.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 4 weeks for at least 4-6 doses, then interval adjusted to every 4-8 weeks based on CST and visual acuity evaluations.
Macular retinal edema 6 mg (0.05 mL) by intravitreal injection every 4 weeks.
Contraindications
- Active or suspected ocular or periocular infections, including viral diseases of the cornea and conjunctiva (active epithelial herpes simplex keratitis, vaccinia, varicella), mycobacterial infections, and fungal diseases
- Glaucoma with cup to disc ratios greater than 0.8
- Torn or ruptured posterior lens capsule due to risk of migration into the anterior chamber
- Known hypersensitivity to any components of this product
- Ocular or periocular infection
- Active intraocular inflammation
- Known hypersensitivity to faricimab or any excipient in VABYSMO
Adverse Reactions
Most common (>=20%) Cataract, increased intraocular pressure, conjunctival hemorrhage
Serious Elevated IOP with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection (including herpes simplex), globe perforation
Postmarketing Endophthalmitis, retinal detachment, implant misplacement with ocular tissue injury, device dislocation with corneal edema or decompensation, hypotony of the eye
Most common (>=1%) Conjunctival hemorrhage, cataract, vitreous detachment, vitreous floaters, intraocular pressure increased, eye pain, intraocular inflammation, retinal pigment epithelial tear, eye irritation, lacrimation increased, ocular discomfort
Serious Endophthalmitis, retinal detachment, increase in intraocular pressure, thromboembolic events, retinal vasculitis and/or retinal vascular occlusion
Postmarketing Retinal vasculitis with or without retinal vascular occlusion
Pharmacology
Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting multiple inflammatory cytokines, resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells.
Faricimab is a humanized bispecific antibody that inhibits two pathways by binding to VEGF-A and Ang-2; VEGF-A inhibition suppresses endothelial cell proliferation, neovascularization, and vascular permeability, while Ang-2 inhibition promotes vascular stability and desensitizes blood vessels to the effects of VEGF-A.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ozurdex
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Vabysmo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Ozurdex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vabysmo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ozurdex
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Vabysmo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Ozurdex.
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OzurdexView full Ozurdex profile
VabysmoView full Vabysmo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.